Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is a clinical-stage biotechnology company developing a portfolio of molecular glue degraders, or MGDs, which are small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. The company's… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Monte Rosa Therapeutics, Inc. does
In the company’s own words
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is a clinical-stage biotechnology company developing a portfolio of molecular glue degraders, or MGDs, which are small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. The company's proprietary QuEEN discovery engine enables rational, target-centric discovery and development of MGDs designed to address proteins previously considered undruggable or inadequately drugged by conventional therapeutic approaches.
The company operates with research and development facilities in Boston, Massachusetts and Basel, Switzerland. Monte Rosa's core technology platform focuses on inducing engagement between E3 ligases and target proteins to trigger ubiquitin-mediated protein degradation. The company has built a proprietary library comprising over 75,000 rationally designed MGD molecules representing more than 1,000 unique low molecular weight scaffolds.
Monte Rosa's clinical pipeline includes three programs in development. MRT-6160, a VAV1-directed MGD for immune-mediated diseases, was licensed to Novartis in October 2024 under a global exclusive development and commercialization agreement. MRT-8102, a NEK7-directed MGD targeting NLRP3 inflammasome-driven inflammatory diseases including atherosclerotic cardiovascular disease and gout, is advancing through Phase 1 studies. MRT-2359, a GSPT1-directed MGD for metastatic castration-resistant prostate cancer, is in Phase 1/2 clinical development.
The company also maintains preclinical programs targeting cyclin E1 and cyclin-dependent kinase 2 for oncology applications. Beyond its internal pipeline, Monte Rosa has established strategic collaborations with Roche and Novartis to advance MGD discovery across oncology, neurology, and immunology indications.
Monte Rosa's business model combines internal development of select programs with strategic partnerships to maximize therapeutic and commercial potential. The company's competitive advantages include its proprietary AI and machine learning algorithms for protein surface characterization, high-throughput screening and proteomics capabilities, and its continuously expanding MGD library. More information is available at www.monterosatx.com.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1826457
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Monte Rosa Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Monte Rosa Therapeutics, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Monte Rosa Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Monte Rosa Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Monte Rosa Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Monte Rosa Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”